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Abstract Magnetic resonance imaging (MRI) is increas-
ingly being used in the diagnostic work-up of patients
with multiple myeloma. Since 2014, MRI findings are
included in the new diagnostic criteria proposed by the
International Myeloma Working Group. Patients with
smouldering myeloma presenting with more than one
unequivocal focal lesion in the bone marrow on MRI
are considered having symptomatic myeloma requiring
treatment, regardless of the presence of lytic bone
lesions. However, bone marrow evaluation with MRI
offers more than only morphological information regard-
ing the detection of focal lesions in patients with MM.
The overall performance of MRI is enhanced by apply-
ing dynamic contrast-enhanced MRI and diffusion
weighted imaging sequences, providing additional func-
tional information on bone marrow vascularization and
cellularity.
This pictorial review provides an overview of the most
important imaging findings in patients with monoclonal
gammopathy of undetermined significance, smouldering my-
eloma and multiple myeloma, by performing a ‘total’ MRI
investigation with implications for the diagnosis, staging and
response assessment.
Main message
•Conventional MRI diagnoses multiple myeloma by assessing
the infiltration pattern.
• Dynamic contrast-enhanced MRI diagnoses multiple myelo-
ma by assessing vascularization and perfusion.
• Diffusion weighted imaging evaluates bone marrow compo-
sition and cellularity in multiple myeloma.
• Combined morphological and functional MRI provides op-
timal bone marrow assessment for staging.
• Combined morphological and functional MRI is of consid-
erable value in treatment follow-up.
Keywords Multiple myeloma .Magnetic resonance
imaging . Dynamic contrast-enhancedMRI . Diffusion
weighted imaging . Response assessment
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Introduction
Multiple myeloma (MM) is a plasma cell dyscrasia, charac-
terized by a proliferation and accumulation of monoclonal
plasma cells [1]. The disease evolves from an asymptomatic
premalignant stage, monoclonal gammopathy of undeter-
mined significance (MGUS), over smouldering multiple my-
eloma (SMM), to symptomatic MM with end-organ damage,
such as hypercalcemia, renal impairment, anaemia and bone
disease [2, 3].
The diagnosis ofMMmainly relies on the demonstration of
bone marrow plasmacytosis and/or demonstration of mono-
clonal proteins (M-proteins) in the serum or urine and/or de-
tection of end-organ damage, especially (lytic) bone lesions
[1], based on the International Myeloma Working Group
(IMWG) diagnostic criteria reported in 2014 [4–6].
Conventional radiographs used to be the gold standard in
the detection of bone lesions in myeloma. However, the de-
tection limit and sensitivity of conventional radiography for
(lytic) bone lesions is low [7]. In the past 10 years, advances
have been made in imaging technology, with a more wide-
spread use of magnetic resonance imaging (MRI), low dose
multidectector computed tomography (MDCT) and 18F-
fluoro-deoxyglucose positron emission tomography (18F-
FDG PET)/18F-FDG PET-CT to assess lytic bone lesions,
but also early stages of bone marrow infiltration [4].
MRI remains themost sensitive and specific imagingmethod
for the detection of bone marrow infiltration, before mineralized
bonehasbeendestroyed [8].Thepresenceofmore thanone focal
lesion onMRI (> 5mm) is therefore enough to defineMM[4, 9].
Fig. 1 Coronal T1-weighted (left) and T2-weighted STIR (right) coronal
whole body MR images displaying a diffuse marrow infiltration in the
spine, pelvis, femora, humeri, ribs and scapulae. Lesions appear
hypointense on T1-weighted images and hyperintense on the STIR
images. Remark the good contrast resolution of STIR images in
revealing infiltration of the ribs: ‘white ribs sign’
Fig. 2 Sagittal T1-weighted (left) and fat-suppressed T2-weighted (right)
images of the spine displaying a diffuse bone marrow infiltration of the
cervical, thoracic, lumbar and sacral spine with low signal intensity on
T1- and intermediate to high signal intensity on fat-suppressed T2-
weighted images
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However, there is an increasing awareness that anatomical ap-
proaches based onmeasurements of tumour size have significant
limitations for assessing therapy response [10]. There is evidence
that the detection rate and overall performance of MRI could be
enhancedwhen information on bonemarrow cellularity and vas-
cularization is added, by applying functional MRI techniques,
such as diffusion weighted imaging (DWI) and dynamic
contrast-enhanced imaging (DCE-MRI), respectively [11, 12].
In this pictorial review, a practical guideline for a ‘total’MRI
evaluation is presented, including information fromconventional
MRI, DCE-MRI andDWI, providing a completemorphological
and functional evaluation of patients with plasma cell disease.
MR imaging techniques
Conventional SE MRI
The most frequently used MR sequences for the evaluation of
bone marrow are conventional T1-weighted spin-echo (T1-
weighted) and T2-weighted spin-echo (T2-weighted) se-
quences. The signal intensities on MR images are based on
the proportionate composition of red and yellow marrow and
to a lesser extent mineralized matrix [13, 14] (Fig 1).
T1-weighted images are best to evaluate bone mar-
row because of the high fat content interspersed with
hematopoietic elements, appearing hyperintense com-
pared to muscle and intervertebral disc [15]. Fat pro-
tons have relatively long T2-relaxation times and ap-
pear iso- to hypointense compared to the subcutaneous
fat on T2-weighted images [13]. Bone marrow contrast
can be accentuated by using fat-suppression (fs) se-
quences. The chemically selective fat-suppression
technique STIR tends to produce more homogenous
fat-suppression than T2-weighted images with fat suppression
[15]. Lesions with a high cellularity and high amount of water
are readily visible on STIR images as hyperintense structures,
with corresponding hypointensity on T1-weighted images
[13, 16] (Fig 2).
Our standard myeloma whole body conventional MR pro-
tocol consists of T1-weighted and STIR images of the body in
the coronal plane and sagittal T1- and fsT2-weighted images
of the spine (Figs. 1 and 2).
Fig. 4 Five types of time-intensity curves (TICs) have been described.
Type 1 (blue) demonstrates no enhancement, whereas type 2 (green)
illustrates a slow sustained enhancement. Type 3 (purple), 4 (orange)
and 5 (red) are characterized by a steep and fast first pass enhancement;
in type 3 this is followed by a sustained late enhancement; in type 4 this is
followed by a wash-out of contrast medium caused by a small interstitial
space. The steep wash-in of type 5 is followed by a stable late
enhancement
Fig. 3 A parasagittal dynamic contrast-enhanced MR image is displayed
with regions of interest (ROI) drawn in the aorta (red circle), paraspinal
muscle (green rectangle), vertebra T10 (yellow polygon) and L3 (blue
polygon). ROI-selection in the vertebrae should exclude the entrance of
the vertebral vessels and the endplates. This method provides a
corresponding time-intensity curve displayed on the right, providing
information on tissue vascularization, perfusion, vessel permeability and
volume of the interstitial space
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Dynamic-contrast enhanced MRI
DCE-MRI can be used to detect and monitor changes in bone
marrow microcirculation as a result of myeloma-induced an-
giogenesis and changes in tumour blood flow and vascular
permeability. The process of angiogenesis plays a role in the
development, growth, and prognosis of hematologic malig-
nancies [17]. The newly formed blood vessels are disorga-
nized, fragile and tortuous with an increased permeability
due to large fenestrations in the vessel walls [18].
DCE-MRI is an imaging technique that investigates in a
non-invasivemanner the neoangiogenesis of tumoral tissue by
providing clinically useful information on tissue vasculariza-
tion, perfusion, capillary permeability and composition of the
interstitial space [19]. A bolus of gadolinium-based contrast
medium is injected intravenously, and imaging is performed
during and immediately after injection by making sequential
images of the spine, eight parallel sagittal slices per series
followed by 74 consecutive series during the first 2 min.
Typically a fat-saturated T1-weighted ultrafast sequence of
the thoracolumbar spine is executed, followed by a static fat-
saturated spin-echo T1-weighted sequence [19, 20].
The temporal changes that occur during passage of the
contrast bolus are depicted in time-intensity curves (TIC).
These curves provide useful information on the amount of
contrast medium diffusing from the intravascular into the
extravascular space and on the kinetics of this process.
During the first pass of the contrast bolus, there is an
immediate unidirectional flow from the intravascular to
the extracellular space, called ‘wash-in’. After the first
pass a decrease in concentration of contrast medium and
signal intensity occurs by intravascular dilution, leakage
into the tissues and renal clearance, resulting in a steady
state. If the intravascular concentration of contrast medi-
um drops under the interstitial concentration level, diffu-
sion takes place in opposite direction until all contrast is
eliminated: this is called ‘wash-out’ [19–21].
TICs, provided by the region-of interest method, allow
calculation of semi-quantitative parameters that depict the
characteristics on vascularity and perfusion of myeloma infil-
trated bone marrow (Fig 3) [19, 20, 22]. A quantitative anal-
ysis of DCE imaging data can be performed using mathemat-
ical models that take into account the enhancement kinetics of
the artery supplying the area studied. Pharmacokinetic models
depict changes in tissue contrast concentrations instead of sig-
nal intensity changes over time [23, 24].
This review is focusing on the qualitative interpreta-
tion of TICs based on the shape of the curve, providing
valuable information on the degree of contrast diffusion.
A classification of five types of curves is described in
Fig. 5 Example of diffusion
weighted b-value images b0-
b200-b600-b1000. The upper
sequence demonstrates the b-
value images of a patient with
monoclonal gammopathy of
undetermined significance, the
lower sequence images belong to
a patients with multiple myeloma.
The signal intensity of myeloma
lesions are typically high on b-
value images, due to the low
amount of fat cells, increased
cellularity and water amount.
Remark the good visibility of the
vertebral bodies and spinous
processes in this patient with
multiple myeloma
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the literature (Fig 4) [20, 22]. MM bone marrow infil-
tration is typically characterized by type 4 curves, and
less frequently type 3 or 5 curves. Type 1 and 2 curves
typically occur in healthy persons or patients with
MGUS [19, 20, 22, 25].
Diffusion weighted imaging
DWI is a technique derived from MRI and is increasingly
being used to assess bone marrow because of its sensitivity
to cell density, the relative content of fat and marrow cells,
water content and bone marrow perfusion [26]. The signal
intensity of DWI relies on the stochastic Brownian motion
or self-diffusion of water molecules at microscopic level with-
in tissues [27]. This Brownian motion of water molecules in
the interstitium allows quantifying the cellularity of tissues:
Fig. 6 MR images of a patient with monoclonal gammopathy of
undetermined significance, with 5 % plasma cells on bone marrow
biopsy. a T1-weighted and fat-suppressed T2-weighted images of the
thoracolumbar spine displaying normal bone marrow signal intensities,
hyperintense on T1 and hypointense on fat-suppressed T2-weighted
images. b DWI b1000 images with normal appearing bone marrow, low
signal intensity due to the high amount of fat and low cellularity with low
water diffusivity. c Time-intensity curve derived from DCE-MR imaging
with a TIC type 1 (L3 - blue) and type 2 (T10 - yellow) curve,
corresponding to a normal vascularization of the bone marrow, no signs
of neoangiogenesis
Fig. 7 MR images of a patient with smouldering multiple myeloma,
15 % plasma cells on bone marrow biopsy. a T1-weighted and fat-
suppressed T2-weighted images of the thoracolumbar spine displaying
altered bone marrow signal intensities, with slight diffuse signal decrease
on T1 images without significant changes on T2-weighted images. b
Normal signal intensity on b1000 images, due to the residual high
amount of fat cells in the bone marrow. c Time-intensity curve derived
from DCE-MR imaging with TIC type 1, corresponding to a normal
vascularization of the bone marrow without signs of neoangiogenesis
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Fig. 8 MR images of a patient with symptomatic multiple myeloma,
30 % plasma cells on bone marrow biopsy. a T1-weighted and T2-
weighted STIR coronal images of the body and b T1-weighted and fat-
suppressed T2-weighted images of the thoracolumbar spine displaying a
significant decrease of signal intensity on T1-weighted images with a
corresponding increased signal intensity on T2-weighted images,
diffuse infiltration pattern, and also remark the additional focal lesions
in the vertebral bodies of T2 and T9 (arrows). c Increased signal intensity
on DWI b1000 images, due to a decrease in bone marrow fat cells,
increased cellularity, and water amount with corresponding increase in
water diffusivity. d Increased angiogenesis, perfusion and vascular
permeability displayed in a time-intensity curve type 4, with early
wash-out of the contrast medium
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Fig. 9 Bone marrow infiltration
patterns. a Normal appearing
bone marrow, b focal (arrow) and
c diffuse myeloma infiltration
pattern, d combination of focal
and diffuse infiltration and finally
e salt-and-pepper infiltration
pattern
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cellular tissues like solid tumours are characterized by a small
interstitium, which restricts water motion [10, 28].
Sagittal diffusion weighted images of the spine in this re-
view are obtained with echoplanar imaging using different b
values (0-200-400-600-1000 s/mm2). The signal losses in the
tissues are proportional to both free motion of water molecules
and the diffusion gradient strength used [27].
Initial assessment of bone marrow disease on DWI are
usually made by visually assessing the signal intensity on high
b-value images (usually b1000), as high signals correspond to
bone marrow infiltration (Fig 5). A DWI investigation is
scored ‘positive’ if hyperintense focal lesions or diffuse
hyperintense vertebral bodies can be seen on high b-value
images, indicating diffusion restriction of water in highly
cellular tissue with a small interstitial space [16, 26]. This
method of assessment is practically useful and clinically
appealing for both radiologists and referring physicians [29],
because lesions are more conspicuous on this type of images.
The quantified parameter derived fromDWI is the apparent
diffusion coefficient (ADC), which is a direct indicator of
water motion within extracellular and intracellular space and
is thus directly related to tissue cell density [30].
Yellow marrow appears hypo-intense on b-value images
with low ADC values, related to low cell density, with an
abundance of fat cells, and reduced water proton diffusivity,
due to the hydrophobic nature of fat and lower bone marrow
perfusion compared to red marrow. Red bone marrow has a
lower adiposity and higher water content, which contributes to
the higher signal intensity on b-value images and higher ADC
values [16, 26] (Fig 6).
Monoclonal gammopathy of undetermined
significance and smouldering myeloma
Patients with MGUS have a normal bone marrow appearance
on MRI, hyperintense on T1-weighted images (high fat con-
tent) and hypointense on fsT2-weighted images (low water
content) [9, 16, 17] (Figs 6a and 7a). The presence of diffuse
infiltration of the bone marrow, and especially the presence
and number of focal lesions are significant prognostic factors
for progression fromMGUS or SMM to MM [9, 11, 31]. The
IMWG consensus statement now recommends that SMM pa-
tients with more than one unequivocal focal lesion
(diameter>5 mm) should be considered to have symptomatic
myeloma that requires treatment. Patients with equivocal focal
lesions should repeat the MRI after 3–6 months and in case of
MRI progression, patients should be considered as symptom-
atic patients who need therapy. Patients withMGUS andMRI-
identified focal lesions seem to have an increased risk of pro-
gression to myeloma. To date, the IMWG has not yet recom-
mended MRI as part of the routine workup for patients with
MGUS unless there are clinical features that increase suspi-
cion of progression to MM [7].
There is no increased bonemarrow perfusion in patients with
MGUS compared to healthy controls [32]. Patients withMGUS
typically provide type 1 and type 2 TICs, as does normal fatty
bonemarrow.These types ofTIC represent a lowand slowwash-
in of contrast medium due to low vascularisation, perfusion and
capillary permeability. This is followed by a plateau phase be-
cause of the slowwash-out of contrast medium from the intersti-
tial space back in the intravascular space [20] (Figs 6c and 7c).
Fig. 10 This figure displays the
change in signal intensity on b
images and ADC value during the
disease course from monoclonal
gammopathy of undetermined
significance, over smouldering to
myeloma-infiltrated bone marrow
with plasma cell percentages of
10-25 %, 25-50 % and >50 %,
followed by the changes early and
late after therapy, and compared
to normal red and yellow marrow.
The different diffusion
characteristics are explained by
changes in the amount of fat and
interstitial water, with an
increasing water proton
diffusivity as fat decreases and
interstitial water increases
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MGUS and SMM patients with increased microcircu-
lation patterns on DCE-MRI appear to have a signifi-
cantly higher bone marrow plasmacytosis compared to
patients with a low microcirculation pattern [17]. An
increased bone marrow perfusion is found in transition
from SMM to symptomatic MM [32].
Patients with MGUS present with low ADC values
and low signal intensity on high b-value images, due to
the high restriction of water diffusion, which can be
explained by a higher bone marrow fat content and
lower water content. No differences could be found be-
tween patients with MGUS and SMM. Bone marrow
infiltration has to be high enough to result in a decrease
in fat cells, detectable on conventional and diffusion-
weighted MRI [16] (Figs. 6b and 7b).
Multiple myeloma
Typical myeloma lesions appear hypointense on T1-weighted
images, due to the lower fat content, typically lower than the
muscle and intervertebral disc. On fat-suppressed T2-weighted
images, the lesions appear rather hyperintense due to the high
cellularity and high amount of water [13, 16] (Fig 8a, b).
Predilection sites of MM are the axial skeleton, spine and pelvis,
but also the extra-axial skeleton, ribs, shoulder, skull and proxi-
mal femora. This explains the whole body approach for an
adequate assessment of extent of disease [20, 33]. The infiltration
of the ribs is best appreciated on T2-weighted images with fat
suppression, appearing bright: ‘white ribs sign’ (Figs. 1 and 8a).
Five different patterns of bone marrow infiltration in mul-
tiple myeloma have been identified onMR imaging, including
Fig. 11 These images present the
same patient as in Fig. 8, with
response to therapy, 100 days
after autologous stem cell
transplantation, with 5 % plasma
cells on bonemarrow on biopsy. a
T1-weighted and T2-weighted
STIR coronal images of the body
and b T1-weighted and fat-
suppressed T2-weighted images
of the thoracolumbar spine,
demonstrating a clear increase in
signal intensity on T1-weighted
and decrease on T2-weighted
images, due to reappearance of
normal bone marrow. c There is a
residual high signal intensity on
the b1000 images, due to residual
oedema and necrosis after therapy
despite the return of fat cells,
accompanied by d a decrease in
perfusion due to destruction of the
neovasculature with the
reappearance of a type 1 (L3 -
blue) and type 2 (T10 - yellow)
curve
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a normal appearing marrow, focal infiltration, diffuse disease,
salt-and-pepper involvement or combined focal and diffuse
infiltration (Fig 9) [34, 35]. These infiltration patterns on
MR images have been found to correlate to histological find-
ings on bonemarrow biopsies [35, 36]. In 28% of the multiple
myeloma patients, a normal appearing bone marrow signal is
found in all sequences with high signal intensity on T1-
weighted and low signal on T2-weighted sequences with fat
suppression (Fig 9a). Focal lesions are areas of high signal
intensity on fsT2-weighted sequences. These correspond to
areas of low signal intensity on unenhanced T1-weighted
images. In a few cases, isointense signal is found on
T1-weighted images (Fig 9b). The diffuse infiltration pattern
is characterized by a homogenous decrease of signal on
T1-weighted images and increased signal intensity on
T2-weighted images with fat suppression (Fig 9c). In cases
of high-grade diffuse involvement, the signal intensity is
nearly equal to or lower than the signal intensity of the inter-
vertebral disc on T1-weighted images due to the increase of
water and decrease of fatty components. A focal and diffuse
infiltration pattern can be found in about 11 % of the patients.
On T1-weighted images, the bone marrow signal intensity is
Fig. 12 These images illustrate
the same patient as in Figs. 8 and
10, with a relapse 1 year after
autologous stem cell
transplantation with 30 % plasma
cells in the bone marrow on
biopsy. a T1-weighted and fat-
suppressed T2-weighted images
of the thoracolumbar spine, with a
subtle decrease in signal intensity
on T1-weighted and increase on
T2-weighted images,
reappearance of normal bone
marrow. b The changes are more
clearly illustrated on the b1000
images with apparent increase in
signal intensity, reflecting the
increased cellularity and water
amount compared to the previous
images. c The changes in bone
marrow composition are
accompanied by the return of an
active TIC type 4, due to
neoangiogenesis
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diffusely decreased with additional foci interspersed. Those
foci are often better demarcated on fat-saturated images
(Fig 9d). In about 3 % of the cases on T1-weighted images
but also T2-weighted sequences, the bone marrow presents
with an inhomogeneous salt-and-pepper pattern (Fig 9e) [35].
MM was the first hematological malignancy in which the
diagnostic and prognostic relevance of angiogenesis was dem-
onstrated [37]. Neoangiogenesis in multiple myeloma is respon-
sible for the increase in bone marrow perfusion, reflected by
increasing DCE-MRI related (semi-) quantitative parameters
[38–41]. The most typical TIC in patients with MM is type 4
(Fig 8d). This curve represents a steep wash-in of contrast me-
dium, due to the high vascularization and perfusionwith leakage
through the highly permeable capillaries, followed by an early
wash-out back into the intravascular space because of the small
interstitial space with closely packed plasma cells. Type 3 and
type 5 occur in myeloma patients with a residual moderate size
of the interstitial space, characterized by a wash-out plateau-
phase or increasing enhancement [19, 20].
Myeloma infiltration of the bone marrow is character-
ized by the highest signal intensities on b-value images
and highest ADC values compared to normal bone mar-
row. This is likely to be related to the absence of fat cells,
higher proton density, destruction of trabecular bone, and
high cellularity. The lesions appear as areas of increased
diffusivity compared to the very low diffusion of normal
background marrow (Fig 8c) [16, 26]. The significant
decrease in signal intensity on T1-weighted images oc-
curs rather late in the evolution, in patients with a plasma
cell percentage of 50 % or more, correlating with a high
signal intensity on fsT2-weighted and high b-value im-
ages with high ADC values. The bone marrow infiltration
has to be high enough to result in a decrease in fat cells,
detectable on conventional and diffusion weighted MRI
(Fig 10) [16].
Response assessment
The follow-up of patients with neoplastic bone involvement
after treatment may show evolution in infiltration patterns.
Some of these changes are with no ambiguity indicative of
either disease progression or response to treatment. Evolution
from a normal bone marrow appearance to a focal or diffuse
infiltration pattern, increase in the number and/or size of le-
sions and evolution from focal to diffuse neoplastic infiltration
are indicative of progressive disease. Disappearance of focal
lesions, decrease in their size and/or number and return from
focal or diffuse patterns to a normal bone marrow appearance
are indicative of response. The complete disappearance of
focal lesions and diffuse infiltration may indicate complete
‘imaging’ remission, which does not necessarily correlate
with complete remission at the microscopic level (Fig 11a,
b). Stability in size and appearance of the marrow abnormal-
ities after treatment should be interpreted cautiously: residual
lesions may represent responsive, controlled but still active
disease, or on the contrary ‘cured’ disease with persistence
Fig. 13 T1-weighted image of the sacrum before (top) and after (bottom)
radiation therapy, presenting the appearance of a peripheral halo of fatty
marrow with a characteristic high signal intensity on T1-weighted images
(arrows), indicating response to therapy
Fig. 14 T1-weighted image of the humerus before (left) and after (right)
systemic therapy. Remark the progressive fading of the bone marrow
signal intensity, from hypo-intense to hyperintense signal intensity on
T1-weighted imaging, indicating response to therapy
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of ‘scar’ tissue, whether contrast material injection, study of
perfusion or diffusion parameters will help in this difficult
differential diagnosis remains uncertain. Relapse is character-
ized by the reappearance of one or several new lesions in a
bone marrow that had shown a previous return to normal after
therapy; sometimes it may also take the appearance of pro-
gression of a lesion that had previously shown size regression
or had been stabilized under treatment (Fig 12a) [42].
The response of focal lesions to therapy can be character-
ized, along with size reduction, by the appearance of a periph-
eral halo of fatty marrow, with characteristic high signal inten-
sity on T1-images (Fig 13). This fatty halo sign indicates
lesion response and parallels the appearance of fat within ‘re-
sponse’ or ‘healing’ non-neoplastic conditions, such as chron-
ic benign vertebral fractures, spondylodiscitis or degenerative
disc disease. Lesion response sometimes does not take the
appearance of shrinking, but rather progressive fading of the
marrow abnormalities and return to normal marrow signal
intensity within the lesion (Fig 14) [42].
The first days after therapy (chemotherapy or radiothera-
py), the marrow undergoes cellular death and vascular con-
gestion resulting in oedema, haemorrhage and necrosis in the
bone necrosis, which appears hypointense on T1 and hyper-
intense on the fluid sensitive (STIR/T2-weighted) images
(Fig 15) [34, 43, 44]. This is accompanied by an increase in
ADC and high SI on high b-value images (T2-shine-through
effects of therapy) (Fig 16) [29, 30, 45, 46]. These changes are
followed by a period of fatty marrow conversion, reducing the
overall increase in ADC and signal intensity on b-value im-
ages (Fig 11c) [16, 47]. Several weeks into treatment, the
signal intensity on T1-weighted images of bone marrow drops
again as red marrow appears on the central skeleton during the
phase of hematopoietic recovery [44]. Relapse is character-
ized by an increase in ADC and SI on b1000 images
(Fig 12b) [16].
There is a significant decrease in (semi-) quantitative
parameters and thus vascularization of the bone marrow
after effective therapy [20, 48, 49]. Patients with a
complete response (CR) after therapy, typically present
with type 1 and 2, indicating low and slow enhancing
areas in the bone marrow with normal vascularization
(Fig 11d). The change in type of curve is dependent on
the type of treatment, depth of response to treatment,
baseline neo-angiogenesis and amount of normal red
Fig. 15 T1-weighted (top) and
T2-weighted STIR (bottom)
images of newly diagnosed
myeloma patient a with diffuse
infiltration of the bone marrow
and a large focal lesion in the right
intertrochanteric region (arrows).
Five years after receiving
systemic therapy and local
irradiation on the right
intertrochanteric region b there is
an increase in signal intensity in
the centre of the focal lesion on
STIR images compatible with
necrosis. Also remark the broad
fatty halo surrounding the lesion.
Both of these imaging findings
indicate good response to therapy
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marrow [20]. Relapse is characterized by the re-
appearance of a type 3–5 curve, depicting active dis-
ease (Fig 12c) [20, 50].
Summary
The value of a ‘total’MRI investigation is clarified in Table 1.
Normal bone marrow (mean age of 40 years) is charac-
terized by a low signal intensity on T1-weighted images
and a high signal intensity on fsT2-weighted and b-value
images, with corresponding ADC-value of 2.94 × 10−4
mm2/s. This can be explained by the high amount of water
and vascularization of hematopoietic marrow accompa-
nied by low amount of fat cells. Normal fatty bone marrow
(mean age > 50 years) is characterized by a high signal
intensity on T1-weighted images and low signal intensity
on fsT2-weighted images due to the high amount of fat
cells, and low amount of interstitial water and hematopoi-
etic marrow. This is associated with low signal intensity
on b-value images, low ADC values (2.78 × 10−4 mm2/s)
and low perfusion.
In the development of multiple myeloma, there is a
gradual increase in monoclonal plasma cells in the bone
marrow. The corresponding bone marrow changes are
explained in the table by subdividing MM patients in
groups of increasing plasma cell percentages: 0–10 %,
10–25 %, 25–50 % and >50 %. Increased plamacytosis
in the bone marrow is accompanied by a gradual de-
crease in fat cells and hematopoietic marrow with an
increase in interstitial water. This disease evolution is
reflected in the signal intensities: decrease on T1-
weighted images together with an increase on fsT2-
weighted and b-value images with high ADC values
(4.41 × 10−4 mm2/s, if the plasma cell percentage is
higher than 50 %). The increasing tumour load induces
neoangiogenesis with corresponding increase in vascu-
larization and perfusion, reflected in the TIC, with a
steeper wash in and high amplitude due to the increase
in number of vessels and capillary permeability, follow-
ed by a wash-out.
Early response to therapy is characterized by oedema and
haemorrhage due to cellular death and vascular congestion,
inducing a further increase in interstitial water, ADC-values
and signal intensity on fsT2-weighted and b-value images,
with corresponding decrease in T1 signal intensity. There is
a change in TIC with flattening of the wash-in due to a de-
crease in perfusion, and number of vessels and enhancement
during second pass due to the increased interstitial space.
Several weeks after therapy, there is a normalization of the
bone marrow appearance on MR imaging due to fatty
reconversion.
Pitfalls
A limitation of the qualitative evaluation of DWI is the T2-
shine-through effect. The T2-shine-through effect occurs be-
cause the measured signal intensity on the high b-value im-
ages depends not only on the water proton diffusivity, but also
on the intrinsic tissue T2 relaxation time. As a result, a tissue
may appear to exhibit high signal intensity on high b-value
images, not because of the restricted mobility of the water
protons, but because of the long intrinsic T2 relaxation time
of the tissue. T2-shine-through is observed in benign condi-
tions such as cysts, post-operative seromas or tissue. Similar
appearances can be seen when bone tumours are successfully
treated, particularly when there has been massive liquefaction
necrosis [27, 51]. In order to avoid misinterpretations arising
from visual assessment of the signal intensity on b-value im-
ages, it is essential to correlate the findings with the
Fig. 16 T2-weighted (left) images of a hyperintense focal lesion (white
arrow) a in a thoracic vertebra of a newly diagnosed myeloma patient
with the corresponding b1000 image (right), showing the focal lesion
together with a slightly diffusely increased signal intensity in the all
vertebral bodies. b After systemic treatment and local irradiation on the
focal lesion the signal intensity of the focal lesion increases on the T2-
weighted image, indicating response and tumour necrosis, with residual
hyperintensity on the b1000 image (right), due to the large water amount
after necrosis: T2-shine-through effect
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morphological features on the associated conventional MR
sequences (Fig 16) [27].
Red bone marrow is characterized by the same signal
intensity changes as compared to malignant myeloma
infiltrated bone marrow. This presents a potential diffi-
culty in assessing the bone marrow of younger patients
and patients receiving bone marrow-stimulating factors
after CR [26]. Red bone marrow hyperplasia is also
characterized by an increased water diffusivity and vas-
cularization. This is associated with TIC type 3, 4 or 5,
mostly type 3, with a less steep wash-in and wash-out
due to normal vessel permeability and moderate size of
the interstitial space, high signal intensity on b-value
images and high ADC-values (Fig 17) [16]. Since the
mean age of patients with MM, MGUS or SMM is
higher than 50 years, differentiation from normal bone
marrow is usually not difficult [16, 20]
Other pathological processes in the bone or bone
marrow mimic myeloma lesions by providing the same
signal intensity characteristics on conventional MRI
images, e.g. bone marrow oedema, subchondral geode,
schwannoma, schmorll nodules and scar tissue after
bone marrow biopsy. These lesions can be distinguished
from myeloma by assessing the localization and other
specific features on conventional MRI [27].
Limitation of MRI
MRI has several disadvantages: relatively high costs and long
scanning time, which may be difficult in ill patients [52].
Patients with claustrophobia and metallic implants have to
be excluded from this imaging method [8].
A limited examination protocol consists of coronal T1-
weighted images of the spine, sagittal T1-weighted and
fsT2-weighted or STIR images of the thoracolumbar spine,
followed by dynamic contrast-enhanced and diffusion weight-
ed sequences of the thoracolumbar spine, reducing the exam-
ination time from 90 to 30 min.
Table 1 This table provides an overview of the bone marrow changes
in the disease course of MM, based on information obtained from
conventional MRI (signal intensity on T1- and fat-suppressed T2-
weighted images), dynamic contrast-enhanced MRI (time-intensity
curves and semi-quantitative parameters) and diffusion weighted
images (apparent diffusion coefficient (ADC), b0 and b1000 images).
The different imaging characteristics of normal bone marrow, myeloma
infiltrated bone marrow with plasma cell percentage of 10–25 %, 25–
50 % and >50 %, a focal myeloma lesion, are presented as signal
intensities in grey-scale, followed by the changes early and late after
therapy. The changes in amount of fat cells, water content, ADC-values,
hematopoietic cells, interstitial space and vascularization are described in
a semi-quantitative manner (0/+). This overview, is largely supported by
the literature, but also partly based on experience and some explanations
are currently not statistically proven
monoclonal gammopathy of undetermined significance (MGUS), T1-weighted images (T1), Fat-saturated T2-weighted images (fsT2), apparent diffu-
sion coefficient (ADC); time-intensity curve (TIC)
Figure legend: fat cells (yellow circles), hematopoietic marrow (red dots), interstitial water (blue background), monoclonal plasma cells (black circles)
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Conclusion
A complete MRI investigation of bone marrow in patients
with plasma cell dyscrasias with conventional whole body
MRI, and functional DCE-MRI and DWI sequences of the
thoracolumbar spine, provides insights in the composition
of the bone marrow. A summarizing table of the imaging
methods and bone marrow changes during the course of
the disease is provided, including changes in fat cells and
water amount, bone marrow cellularity, vascularization,
volume of the interstitial space, vessel permeability and
water diffusivity. The obtained information on bone mar-
row changes is of important value in diagnostic work-up
and response assessment.
Fig. 17 MR images of healthy
young subject with normal red
bone marrow. a The bone marrow
appears hypointense on T1-
weighted images (left), without
focal lesions and with a
corresponding high signal
intensity on fat-suppressed T2-
weighted images (right). b There
is a high signal intensity on b1000
images due to the low amount of
fat cells, high cellularity
(hematopoietic cells) and high
amount of water. c The
vascularization and perfusion are
also high (TIC type 4), with an
early wash-out of contrast
medium
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